- Some Cubans depend on sugar water as food shortages bite
- Saudi crown prince says no Israel ties without Palestinian state
- Canada to further cut international student, foreign worker permits
- YouTube launches new TV-focused tools for creators
- White Sox heading for worst season in MLB history
- China the top challenge in US history: senior diplomat
- Hong Kong democracy tycoon's son warns time running out
- New migraine drugs no better than cheap painkillers: big study
- Sean 'Diddy' Combs again denied bail in sex trafficking case
- Brewers clinch division title as MLB playoff race heats up
- Man City blunted by 'giant' Inter in Champions League stalemate
- US stocks dip despite larger Fed interest rate cut
- Man City held by Inter as PSG pinch win in Champions League
- All Blacks recall Beauden Barrett for Australia Test
- Fears of all-out war as new Lebanon device blasts kill 20, wound 450
- Spurs late show saves Postecoglou blushes at Coventry
- PSG snatch late goal to beat Champions League debutants Girona
- Gittens' late double gives Dortmund Champions League win at Brugge
- Man City blunted by Inter in Champions League stalemate
- Hidden talent: French Olympic star Marchand opts for disguise
- MrBeast named in California lawsuit over 'Beast Games' show
- Gauff splits with Gilbert as coach after 14-month run
- Hundreds of thousands at risk in Sudan's El-Fasher: UN
- Harvey Weinstein pleads not guilty to new sex crime charge
- Venezuelan opposition candidate says letter conceding election was coerced
- Ukraine official claims Russian advance in Kursk has been 'stopped'
- X update allows app to bypass Brazil ban: internet providers
- Fears of all-out war as new Lebanon device blasts kill 14, wound 450
- US Fed makes aggressive rate cut, weeks before election
- Arsenal's Odegaard faces lengthy injury absence
- India coal expansion risks massive methane growth: report
- China the top challenge in US history, top diplomat says
- US Fed makes larger half-point cut in first reduction since 2020
- Ronaldo's Al Nassr appoint former AC Milan boss Pioli
- Ainslie 'relieved' as British book place in Louis Vuitton Cup final
- Struggling Roma replace sacked icon De Rossi with Ivan Juric
- Women's NBA will add 15th team in Portland in 2026
- Brazil fires need harsher punishment: environmental police boss
- Boeing to start large temporary furloughs amid Seattle strike
- Fears of all-out war as new Lebanon device blasts kill nine, wound 300
- 'Emergency' declared over falling UK butterfly numbers
- McIlroy outlines threats to golf peace deal
- Stock markets, dollar slip before US rate decision
- Russian advance in Kursk 'stopped': Ukraine official to AFP
- UN members demand end to 'unlawful' Israeli occupation of Palestinian territories
- Snapchat pushes 'safer' platform image, but not everyone agrees
- Three dead, 100 wounded in new wave of Lebanon device explosions
- So where does the oceans' plastic waste come from?
- Allied war heroes buried in Netherlands... 80 years on
- Marsh coy over Australia's choice to open alongside Head
RBGPF | 5.79% | 60.5 | $ | |
CMSC | 0.02% | 25.055 | $ | |
RYCEF | 1.37% | 6.55 | $ | |
RELX | -0.82% | 47.37 | $ | |
GSK | -0.31% | 42.43 | $ | |
NGG | -0.46% | 70.05 | $ | |
SCS | 0.71% | 14.11 | $ | |
BCC | 1.33% | 137.06 | $ | |
RIO | -0.02% | 62.91 | $ | |
JRI | 0.45% | 13.44 | $ | |
AZN | 0.06% | 78.58 | $ | |
BTI | -0.34% | 37.88 | $ | |
VOD | 0.49% | 10.23 | $ | |
BCE | 3.09% | 35.61 | $ | |
CMSD | -0.12% | 24.98 | $ | |
BP | -0.37% | 32.43 | $ |
The quest for a universal coronavirus vaccine
As vaccine makers rush to stamp out new Covid-19 variants, some scientists have set their sights higher, aiming for a universal coronavirus vaccine that could tackle any future strains and possibly even stave off another pandemic.
Since the race for a first Covid jab supercharged a new generation of vaccine technology, there have been numerous efforts to develop pan-coronavirus immunisation.
Drew Weissman of the University of Pennsylvania, who was a pioneer of the mRNA technology used in Pfizer's Covid vaccine, is leading one such project.
He said the problem with updating current vaccines to target all existing strains -- a plan announced by Pfizer earlier this month -- is that "new variants are going to appear every three or six months".
After more than two years simply trying to infect more people, he said, the virus is now starting to mutate specifically to get around the immunity gained from vaccines -- much as influenza's constant changing requires an updated shot every year.
"That makes it a little bit trickier, because now you're fighting head-to-head with the virus," Weissman told AFP.
So his team is working on a pan-coronavirus vaccine, which he said has tested well so far.
They are trying to find "highly conserved epitope sequences" -- more integral parts of the virus that cannot mutate readily because it would die without them.
But it's not going to be easy.
"We may have a universal vaccine in two or three years, but we're going to have to keep working on it and changing it over time to keep ahead of the virus," Weissman said.
- Expanding ambitions -
Covid was not the first coronavirus to jump from animals to humans this century: its older relative SARS killed nearly 800 people from 2002-2004, and the Middle East Respiratory Syndrome (MERS) followed in 2012.
When US-based biotech firm VBI Vaccines announced its pan-coronavirus project in the early days of the pandemic in March 2020, it targeted all three.
Francisco Diaz-Mitoma, VBI's chief medical officer, explained the premise by likening each antigen of their proposed vaccine to one of the three primary colours.
The firm hopes to provide antibodies not just for these three -- but also for "the various shades of orange, green, and purple found in between".
"In other words, we are trying to teach the immune system to expand upon the variations of virus it is capable of 'seeing' from the start," he told AFP.
He said VBI's vaccine had shown promising results so far -- including in bats and pangolins -- with clinical studies hoped to start in the coming months ahead of results in early 2023.
The ferritin nanoparticle vaccine effort led by Barton Haynes, director of Duke University's Human Vaccine Institute, has received funding from the US National Institute of Allergies and Infectious Diseases (NIAID).
He told AFP this vaccine, which targets SARS-like viruses but not a broader range of coronaviruses like MERS, had been shown to work well against Omicron.
- 'Leaping one step ahead' -
Pamela Bjorkman of the California Institute of Technology said a true pan-coronavirus vaccine was probably not realistic because there are so many lineages -- some which include common colds.
Her project uses a mosaic nanoparticle approach to target the B lineage of betacoronaviruses, which includes the original SARS-CoV and SARS-CoV-2, the virus that causes the disease Covid.
Bjorkman told AFP that even the "quest" for this specific lineage was comparable to the "many years of effort to make a universal influenza vaccine."
Like Haynes, she said the wide availability of a vaccine depended on how quickly they could begin human trials.
Even if none of the current pan-coronavirus vaccine projects are likely to be rolled out in the next year, their eventual arrival could change the world's relationship with Covid.
"If a pan-coronavirus vaccine is successfully able to establish a broader foundational immunity against coronaviruses, it would allow us, as a global society, to go from being one step behind, to leaping one step ahead of the pandemic," Diaz-Mitoma said.
The broadening horizons of vaccine research could also be one way Covid has forced the world to better prepare for the threat of even worse pandemics ahead.
The US-based Coalition for Epidemic Preparedness Innovations (CEPI) has earmarked $200 million (185 million euros) for pan-coronavirus research.
But it also has a $3.5 billion (3.2 billion euro) plan it hopes will help develop a vaccine targeting "the next Disease X" within 100 days of it emerging -- regardless of whether it is a coronavirus.
D.Schneider--BTB